Skip to main content
Captor Therapeutics S.A. logo

Captor Therapeutics S.A. — Investor Relations & Filings

Ticker · CTX ISIN · PLCPTRT00014 LEI · 259400JHH1S2I2S4O735 WAR Professional, scientific and technical activities
Open in API
Filings indexed 930 across all filing types
Latest filing 2026-06-10 Board/Management Inform…
Country PL Poland
Listing WAR CTX

About Captor Therapeutics S.A.

https://www.captortherapeutics.com/

Captor Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for diseases with high unmet medical needs. The company specializes in Targeted Protein Degradation (TPD), a technology that enables the elimination of disease-causing proteins previously considered "undruggable." Its core research and development activities are centered on creating new treatments for cancer and autoimmune diseases. To achieve this, Captor Therapeutics utilizes its proprietary Optigrade™ platform. This integrated drug discovery engine combines advanced technologies, including structural biology, proteomics, molecular modeling, and protein engineering, to identify and optimize novel drug candidates. The platform is designed to accelerate the development of degraders with superior therapeutic properties, aiming to provide new treatment options for severe conditions.

Recent filings

Filing Released Lang Actions
życiorys (tłumaczenie)
Board/Management Information Classification · 85% confidence The document is a detailed biography of Dr. Andrew Galazka, highlighting his executive roles, board memberships, and senior management experience. It does not present financial results, regulatory filings, or investor presentations, but rather focuses on management/board information. Therefore, it fits the Board/Management Information category (MANG).
2026-06-10 Polish
życiorys
Board/Management Information Classification · 75% confidence The document is a personal biography of Dr. Andrew Galazka, highlighting his senior management and board roles, experiences, and qualifications. It is clearly focused on an individual’s board/management background rather than providing financial results, regulatory compliance details, or investor materials. As such, it fits the definition of a Board/Management Information announcement (MANG).
2026-06-10 English
Aktualizacja informacji dotyczących kandydata na członka Rady Nadzorczej Spółki - Content (PL)
Board/Management Information Classification · 85% confidence The document is a regulatory current report informing about the updated professional CV of a candidate (Andrew Galazki) for the supervisory board, submitted by a shareholder. It concerns board/supervisory management changes and information, not an AGM presentation or full report. Therefore it fits 'Board/Management Information' (MANG).
2026-06-10 Polish
życiorys zawodowy kandydata_PL (tłumaczenie maszynowe)
Regulatory Filings Classification · 20% confidence The document is a standalone professional biography of Dr. Andrew Galazka, machine-translated into Polish, with no indication of a corporate filing, report structure (financial statements, meeting minutes, call transcripts, etc.), or announcement of an event. It does not match any specialized category such as board appointment notice (MANG), investor presentation (IP), or proxy materials (PSI). It contains no voting results, legal notices, or financial figures. It falls into none of the company filing categories and defaults to a general regulatory announcement/fallback.
2026-06-08 Polish
życiorys zawodowy kandydata
Board/Management Information Classification · 90% confidence The document is a standalone executive biography for Dr. Andrew Galazka, detailing his senior management and board-level experience. It does not contain financial performance data or regulatory attestations, nor does it announce an earnings release or dividend. This type of content aligns with Board/Management Information, as it profiles a senior executive likely in connection with a board appointment or management change.
2026-06-08 English
oświadczenie kandydata
Proxy Solicitation & Information Statement Classification · 80% confidence The document is a candidate’s statement (‘Oświadczenie’) submitted to the General Meeting by a nominee for the Supervisory Board, detailing independence and legal qualifications. Such declarations are distributed to shareholders before voting to inform their proxy decision. This aligns with Proxy Solicitation & Information Statement materials (PSI), not a report publication or actual appointment notice.
2026-06-08 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.